461
Views
0
CrossRef citations to date
0
Altmetric
Editorials

Two demyelinating diseases in the brain of a single patient, PML and MS: how to minimize ‘one’ while treating the ‘other’

, , &
Pages 887-890 | Published online: 10 Jan 2014

References

  • Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel, BH. Cultivation of papova like virus from human brain with progressive multifocal leukoencephalopathy. Lancet I, 1257–1260 (1971).
  • Ferenczy MW, Marshall LJ, Nelson CD et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus induced demyelinating disease of the human brain. Clin. Micro Rev. 25, 471–506 (2012).
  • Hamilton RS, Gravell M, Major EO. Comparison of antibody determined by hemagglutination inhibition and enzyme linked immunosorbent assay for JC virus and BK virus. J. Clin. Microbiol. 38, 105–109 (2000).
  • Gorelik L, Lerner M, Bixler S et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol. 68, 295–303 (2010).
  • Berger JR, Houff SA, Gurwell J et al. JC virus antibody status underestimates infection rates. Ann. Neurol. 74(1), 84–90 (2013).
  • Major EO, Frohman EF, Douek DC. JC viremia in natalizumab treated patients with multiple sclerosis. N. Engl. J. Med. 368, 240–2241 (2013).
  • Ryschkewitsch CF, Jensen PN, Major EO. Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants. J. Clin. Virol. 57, 243–248 (2013).
  • Jelic I, Aly L, Binder T et al. T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB 1* o4:01 donors. J. Virol. 87, 3393–3408 (2013).
  • Perkins MR, Ryschkewitsch CF, Leiber JC et al. Changes in JC virus specific T cell responses during natalizumab treatment in natalizumab associated progressive multifocal leukoencephalopathy. PLoS Pathog. 8(11), e1003014 (2012).
  • Frohman EF, Racke MK, Raine CS. Multiple sclerosis – the plague and its pathogensis. N. Eng. J. Med. 354, 942–955 (2006).
  • Bruck W, Gold R, Lund BT et al. Therapeutic decisions in multiple sclerosis moving beyond efficacy. JAMA Neurol. doi: 10.1001/jamaneurol.2013.3510. (2013) (Epub ahead of print).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.